AI Article Synopsis
- A 72-year-old male developed a pulmonary embolism and subsequently a pericardial effusion after undergoing esophagectomy, highlighting a complex medical scenario.
- The initiation of Rivaroxaban for the pulmonary embolism may have contributed to the development of the pericardial effusion, with previous chemoradiotherapy possibly increasing the patient's risk.
- Managing both conditions is challenging, and it’s crucial to involve a coagulation specialist when prescribing Rivaroxaban for esophageal cancer patients.
Article Abstract
Introduction: This is the first reported case of simultaneous presentation of pulmonary embolism and pericardial effusion following esophagectomy. This case illustrates a diagnostic and therapeutic challenge exemplifying the difficulties arising from complex anticoagulant considerations in esophageal cancer.
Patient Case: A 72 year old male undergoes an oncological esophageal resection. Postoperatively the patient develops pulmonary embolism for which he is treated with Rivaroxaban. After starting Rivaroxaban the patient develops a large pericardial effusion.
Discussion: We suspect that the treatment of pulmonary embolism with Rivaroxaban had a causative role in the development of pericardial effusion. Based on literature we suspect that chemoradiotherapy increased susceptibility.
Conclusion: Diagnosis and treatment of simultaneous pulmonary embolism and pericardial effusion remains a challenge. Special consideration should be taken when using Rivaroxaban in esophageal cancer patients; this should always be conducted in consultation with a coagulation specialist.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672252 | PMC |
| http://dx.doi.org/10.1016/j.ijscr.2020.10.090 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!